We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.43%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
-$110M
(-5.2%)
Cap. Flow
-$166M
Cap. Flow
% of AUM
-8.36%
Top 10 Holdings %
Top 10 Hldgs %
54.66%
Holding
88
New
23
Increased
17
Reduced
12
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$115M |
| 2 |
HCA Healthcare
HCA
|
+$108M |
| 3 |
CVRS
CORINDUS VASCULAR ROBOTICS, INC
CVRS
|
+$85.2M |
| 4 |
AKRX
Akorn Inc
AKRX
|
+$79.8M |
| 5 |
RAD
Rite Aid Corporation
RAD
|
+$56.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$68M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$67M |
| 3 |
Biogen
BIIB
|
+$63.6M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$56.2M |
| 5 |
Boston Scientific
BSX
|
+$42.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.27% |
| 2 | Financials | 5.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Perrigo
PRGO
$1.43B
| $24.9M | 1.26% |
+134,900
| New | +$25.7M |
|
27
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
| $22.3M | 1.12% |
+300,000
| New | +$22.2M |
|
28
BioMarin Pharmaceuticals
BMRN
$11.7B
| $22.2M | 1.12% |
+162,500
| New | +$20.1M |
|
|
SGNT
29
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $22.2M | 1.12% |
+912,381
| New | +$21.9M |
|
30
DexCom
DXCM
$28.8B
| $21.4M | 1.08% |
+1,070,000
| New | +$18.8M |
|
31
Arbutus Biopharma
ABUS
$871M
| $20.5M | 1.03% |
1,725,000
+1,006,200
| +140% | +$15.3M |
|
|
TSRO
32
DELISTED
TESARO, Inc.
TSRO
| $16.3M | 0.82% |
276,647
-648,353
| -70% | -$37.2M |
|
|
33
Biogen
BIIB
$30.7B
| $13M | 0.65% |
32,140
-158,560
| -83% | -$63.6M |
|
34
Abbott
ABT
$183B
| $11.3M | 0.57% |
+229,830
| New | +$11M |
|
35
Sarepta Therapeutics
SRPT
$1.64B
| $11.1M | 0.56% |
365,000
-97,700
| -21% | -$2M |
|
36
Zoetis
ZTS
$31.9B
| $10.9M | 0.55% |
+225,530
| New | +$10.8M |
|
37
Assembly Biosciences
ASMB
$516M
| $9.73M | 0.49% |
42,114
+2,531
| +6% | +$488K |
|
|
KND
38
DELISTED
Kindred Healthcare
KND
| $9.15M | 0.46% |
451,206
-1,509,594
| -77% | -$34.6M |
|
39
Collegium Pharmaceutical
COLL
$1.17B
| $8.45M | 0.43% |
+473,664
| New | +$8.19M |
|
40
IQVIA
IQV
$39.1B
| $8.42M | 0.42% |
116,000
+19,504
| +20% | +$1.34M |
|
|
AGN
41
DELISTED
Allergan plc
AGN
| $8.35M | 0.42% |
+27,510
| New | +$8.21M |
|
|
HSTO
42
DELISTED
Histogen Inc. Common Stock
HSTO
| $5.25M | 0.26% |
+5,098
| New | +$5.98M |
|
|
ACGN
43
DELISTED
Aceragen Inc
ACGN
| $4.95M | 0.25% |
9,826
+1,245
| +15% | +$571K |
|
|
44
Teva Pharmaceuticals
TEVA
$41.2B
| $3.73M | 0.19% |
63,200
-1,086,800
| -95% | -$67M |
|
|
CYAD
45
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
| $3.38M | 0.17% |
+65,000
| New | +$3.5M |
|
46
Thermo Fisher Scientific
TMO
$214B
| $3.05M | 0.15% |
23,480
-44,620
| -66% | -$5.82M |
|
|
ELOS
47
DELISTED
Syneron Medical Ltd
ELOS
| $2.8M | 0.14% |
263,400
| – | – |
|
|
IPCM
48
DELISTED
IPC HEALTHCARE INC COM DTD
IPCM
| $2.56M | 0.13% |
+46,300
| New | +$2.35M |
|
49
Tandem Diabetes Care
TNDM
$1.3B
| $2.16M | 0.11% |
+19,960
| New | +$2.48M |
|
50
Universal Health Services
UHS
$9.88B
| $2.12M | 0.11% |
14,900
-210,100
| -93% | -$26.3M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2015 Portfolio in Review
As of Q2 2015, HealthCor Management held 88 positions worth $1.99B, down 5.2% from $2.1B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
HealthCor Management withdrew a net $166M in Q2 2015, closing 35 positions and reducing 12 holdings. Its most notable exit was Viatris, an estimated $68M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Financials.
Against the trend, HealthCor Management opened a new position in HCA Healthcare worth $122M.
- HealthCor Management's largest Q2 2015 buy was HCA Healthcare: 1,350,000 shares worth $122M.
- HealthCor Management added most to Edwards Lifesciences in Q2 2015, an estimated $115M increase.
- HealthCor Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $67M.
- HealthCor Management fully exited Viatris in Q2 2015, selling an estimated $68M.
- HealthCor Management's ten largest holdings make up 55% of its $1.99B portfolio in Q2 2015.
- HealthCor Management opened 23 new positions and closed 35 in Q2 2015.
- HealthCor Management's portfolio value fell 5.2% quarter-over-quarter to $1.99B.
Based on HealthCor Management's 13F filing for Q2 2015, filed 14 Aug 2015.